Last reviewed · How we verify

NCT06106724

Primary Precutting Versus Conventional Over-the-Wire Sphinchterotomy For Managment Of Large Common Bile Duct Stones

Status unknown NA Last updated 30 October 2023
What this trial tests

NA trial testing sphincterotomy in Calcular Obstructive Jaundice in 50 participants. Status unknown.

Timeline
15 September 2023
Primary endpoint
15 September 2024
15 September 2024

Quick facts

Lead sponsorSohag University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment50
Start date15 September 2023
Primary completion15 September 2024
Estimated completion15 September 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Eligibility, any sex, with Calcular Obstructive Jaundice. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

During the last decades, endoscopic retrograde cholangiopancreatography (ERCP) has become the standard of care for the treatment of many pancreaticobiliary diseases \[Canena et al., 2014\]. However, ERCP is a challenging technique with a slow learning curve and is associated with complications, some of them lifethreatening \[Chandrasekhara et al., 2017\]. Post-ERCP pancreatitis (PEP) is the most common and serious complication after ERCP \[Testoni et al., 2016\]. A systematic survey of prospective studies including 16,885 patients reported an incidence of PEP of approximately 3.5%. Severe pancreatitis was found in 11% of the cases, and death occurred in 3% of PEP cases \[Andriulli et al., 2007\]. Therefore, many attempts to reduce the rate of this complication have been pursued. Selective cannulation of the common bile duct (CBD) is still considered to be a prerequisite for biliary sphincterotomy. Despite the use of various endoscopic retrograde cholangiopancreatography (ERCP) catheters and wire-guided sphincterotomes, CBD cannulation has been reported to fail in 5 % - 20 % of cases \[Larkin and Huibregtse, 2001\]. Precut sphincterotomy can allow access to the bile duct in such cases and is widely performed by expert endoscopists when there is a clear indication for endoscopic intervention. However, the use of precut sphincterotomy remains controversial because reported complication rates of the widely practiced needle-knife sphincterotomy (NKS) technique vary between 5 % and 20 % \[Shakoor and Geenen, 1992\]. Precut sphincterotomy, which includes needle-knife papillotomy (NKP), septotomy, and needle-knife fistulotomy (NKF), is often performed to facilitate access to the common bile duct of patients with difficult biliary access (DBA). Furthermore, NKF has been recommended as the preferred technique for precutting by the European Society of Gastrointestinal Endoscopy \[Testoni et al., 2016\] and the latest International Consensus\[Liao et al., 2017\]. The success of NKS also depends on the expertise of the endoscopist, and the consensus opinion is that this technique should only be performed by experienced endoscopists \[Baillie,1997 \]. In contrast to NKS, incision of the papilla of Vater using an Erlangen-type precut sphincterotome has been previously reported by Binmoeller et al group to be an effective and safe auxiliary method for achieving access to the CBD after failed cannulation attempts \[Binmoeller et al., 1996\]. The definition of DBA varied widely \[Mariani et al., 2016\]. The latest guidelines for the definition of DBA differed widely from the latest guideline of The European Society of Gastrointestinal Endoscopy (defining DBA as the presence of ≥1 of the following: \>5 contacts with the papilla while attempting to cannulate; \>5 minutes spent attempting to cannulate following visualization of the papilla; \>1 2 unintended pancreatic duct cannulation or opacification) \[Testoni et al., 2016\]. and the International Consensus Panel (defining DBA as the inability to achieve selective biliary cannulation by the standard ERCP technique within 10 minutes or up to 5 attempts or failure of access to the major papilla) \[Liao et al., 2017 \].

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06106724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing